If you made any changes in Pure these will be visible here soon.

Personal profile

Education

  • 1994 中山醫學院醫學系學士

Experience

  • 2018- 臺北醫學大學癌症生物學與藥物研發研究所助理教授
  • 2016-2018 臺北醫學大學癌症生物學與藥物研發博士學位學程助理教授
  • 2007 臺北榮民總醫院義務特約醫師主治醫師
  • 2006-2007 國防醫學院三軍總醫院癌症病房主治醫師
  • 2000-2001 國立臺灣大學醫學院附設醫院血液腫瘤科住院醫師
  • 1995-2006 國家衛生研究院癌症研究所主治醫師
  • 1994-1995 臺北市立仁愛醫院麻醉科住院醫師

Fingerprint Dive into the research topics where Her-Shyong Shiah is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 17 Similar Profiles
oxaliplatin Medicine & Life Sciences
gemcitabine Medicine & Life Sciences
Leucovorin Medicine & Life Sciences
Fluorouracil Medicine & Life Sciences
Pancreatic Neoplasms Medicine & Life Sciences
Hepatocellular Carcinoma Medicine & Life Sciences
Neoplasms Medicine & Life Sciences
Maximum Tolerated Dose Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Projects 2018 2018

新聘教師研究補助

Shiah, H.

1/1/1812/31/18

Project: B - Project of TMUg - Research Grants for Newly Hired Faculty

Research Output 1991 2018

  • 667 Citations
  • 15 h-Index
  • 26 Article
  • 1 Letter

Effective Sirolimus Treatment for Refractory Spindle Cell Haemangioma

Ho, C. B., Hsieh, K., Chen, W. Y., Lin, Y. T., Chiou, J. F., Lee, H. L. & Shiah, H. S., May 11 2018, In : British Journal of Dermatology.

Research output: Contribution to journalArticle

Sirolimus
Hemangioma
Blood Vessels
Enchondromatosis
Therapeutics
1 Citation (Scopus)
Acetylgalactosamine
Hyperoxia
NF-kappa B
Lung Injury
Threonine
6 Citations (Scopus)

Effects of Dang-Gui-Bu-Xue-Tang, an herbal decoction, on iron uptake in iron-deficient anemia

Huang, G. C., Chen, S. Y., Tsai, P. W., Ganzon, J. G., Lee, C. J., Shiah, H. S. & Wang, C. C., Mar 2 2016, In : Drug Design, Development and Therapy. 10, p. 949-957 9 p.

Research output: Contribution to journalArticle

ferrous sulfate
Anemia
Iron
Hemoglobins
Caco-2 Cells
62 Citations (Scopus)

A KRAS mutation status-stratified randomized phase II trial of gemcitabine and oxaliplatin alone or in combination with cetuximab in advanced biliary tract cancer

Chen, J. S., Hsu, C., Chiang, N. J., Tsai, C. S., Tsou, H. H., Huang, S. F., Bai, L. Y., Chang, I. C., Shiah, H. S., Ho, C. L., Yen, C. J., Lee, K. D., Chiu, C. F., Rau, K. M., Yu, M. S., Yang, Y., Hsieh, R. K., Chang, J. Y., Shan, Y. S., Chao, Y. & 13 others, Chen, L. T., Chin, Y. H., Chung, T. R., Yu, W. L., Lee, M. H., Lin, L. F., Lin, P. C., Wu, Y. L., Wang, H. L., Lu, L. J., Chen, S. Y., Wu, C. C. & Wei, T. C., May 1 2015, In : Annals of Oncology. 26, 5, p. 943-949 7 p., mdv035.

Research output: Contribution to journalArticle

oxaliplatin
gemcitabine
Biliary Tract Neoplasms
Mutation
Exanthema
46 Citations (Scopus)

Phase i study of nanoliposomal irinotecan (PEP02) in advanced solid tumor patients

Chang, T. C., Shiah, H. S., Yang, C. H., Yeh, K. H., Cheng, A. L., Shen, B. N., Wang, Y. W., Yeh, C. G., Chiang, N. J., Chang, J. Y. & Chen, L. T., Jan 1 2015, In : Cancer Chemotherapy and Pharmacology. 75, 3, p. 579-586 8 p.

Research output: Contribution to journalArticle

irinotecan
Tumors
Pharmacokinetics
Toxicity
Neoplasms